A clinical trial reported that erlotinib, an EGFR inhibitor approved by the Food and Drug Administration, decreased serum CCL2 levels in non-small-cell lung cancer (NSCLC) patients (73). This evidence concerns the gene EGFR and non-small cell lung carcinoma.